VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1045-1050

  Shahin, Mohamed Hossam A ^a   Cavallari, Larisa H ^b   Perera, Minoli A ^c   Khalifa, Sherief I ^d   Misher, Anne ^e   Langaee, Taimour ^a   Patel, Shitalben ^b   Perry, Kimberly ^c   Meltzer, David O ^c   McLeod, Howard L ^e   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d QATAR UNIVERSITY   (Qatar)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

Egyptians; Pharmacogenetics; Polymorphism; VKORC1 Asp36Tyr; Warfarin

Indexed keywords

MENADIONE EPOXIDE; WARFARIN;

ALLELE; ARTICLE; DISEASE CARRIER; EGYPT; GENE; GENE FREQUENCY; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ALLELES; COHORT STUDIES; EGYPT; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; GEOGRAPHY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84878623834     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0789     Document Type: Article

References (31)

1. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
2. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010; 55: 2813-2815.
3. Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 2012; 125: 1964-1966.
4. Li C, Schwarz UI, Ritchie MD, et al. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009; 113: 3925-3930.
5. Aquilante CL, Langaee T Y, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
6. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009; 30: 375-386.
7. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
8. Johnson JA, Cavallari LH, Beitelshees AL, et al. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther 2011; 90: 519-531.
9. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
10. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
11. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
12. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008; 84: 332-339.
13. Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol 2012; 8: 563-576.
14. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-2480.
15. Aklillu E, Leong C, Loebstein R, et al. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008; 111: 3903-3904.
16. Scott SA, Edelmann L, Kornreich R, et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495-500.
17. Efrati E, Elkin H, Sprecher E, et al. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf 2010; 5: 190-193.
18. Bodin L, Perdu J, Diry M, et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 6: 1436-1439.
19. Cen HJ, Zeng WT, Leng XY, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010; 70: 234-240.
20. Burmester JK, Berg RL, Glurich I, et al. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. Clin Med Res 2011; 9: 119-124.
21. Pavani A, Naushad SM, Rupasree Y, et al. Optimisation of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 2012; 12: 306-311.
22. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12: 953-963.
23. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21: 130-135.
24. Marsh S, King CR, Garsa AA, et al. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005; 311: 97-114.
25. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-893.
26. Ely B, Wilson JL, Jackson F, et al. African-American mitochondrial DNAs often match mtDNAs found in multiple African ethnic groups. BMC Biol 2006; 4: 34.
27. Bress A, Patel SR, Perera MA, et al. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 2012; 13: 1925-1935.
28. D'Ambrosio RL, D'Andrea G, Cafolla A, et al. A new vitamin K epoxide reduc-tase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J Thromb Haemost 2007; 5: 191-193.
29. Harrington DJ, Gorska R, Wheeler R, et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Hae-most 2008; 6: 1663-1670.
30. Watzka M, Geisen C, Bevans CG, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 2011; 9: 109-118.
31. Kurnik D, Qasim H, Sominsky S, et al. Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Hae-most 2012; 108: 781-788.